Systemic Tumor Embolism Mimicking Gefitinib (‘IRESSA’)-induced Interstitial Lung Disease in a Patient with Lung Cancer

UMEMURA Shigeki; KISHINO Daizo; TABATA Masahiro; KIURA Katsuyuki; HOTTA Katsuyuki; NISHII Kenji; TANIMOTO Yasushi; KANEHIRO Arihiko; NOTOHARA Kenji; UEOKA Hiroshi; TANIMOTO Mitsune

Art

J-GLOBAL ID：200902233096687121 Reference number：05A0825116

Systemic Tumor Embolism Mimicking Gefitinib (‘IRESSA’)-induced Interstitial Lung Disease in a Patient with Lung Cancer

肺癌患者における全身性腫よう塞栓症に類似しているゲフィチニブ(イレッサ)による間質性肺炎

Publisher site Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=05A0825116&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=05A0825116&from=J-GLOBAL&jstjournalNo=Z0157B") }}

Author (11)： , , , , , , , , , ,
Material：
Volume： 44 Issue： 9 Page： 979-982 Publication year： Sep. 2005
JST Material Number： Z0157B ISSN： 0918-2918 Document type： Article
Article type：原著論文 Country of issue： Japan (JPN) Language： ENGLISH (EN)

,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=05A0825116&from=J-GLOBAL&jstjournalNo=Z0157B") }}

Clinical application of antitumor(=antineoplastic)drugs , Drug therapy(=pharmacotherapy)for tumors , Tumors(=neoplasms)of respiratory system

Reference (20)：

ARTEAGA, CL. Tyrosine kinase inhibitors-ZD1839 (IRESSA). Curr Opin Oncol. 2001, 13, 491-498
BASELGA, J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002, 20, 4292-4302
RANSON, M. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors : results of a phase I trial. J Clin Oncol. 2002, 20, 2240-2250
HERBST, RS. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors : results of a phase I trial. J Clin Oncol. 2002, 20, 3815-3825
INOUE, A. Severe acute interstitial pneumonia and gefitinib. The Lancet. 2003, 361, 137-139

ｍore...

, , , , , , ,

Return to Previous Page